Compare iShares Core MSCI EAFE ETF (IEFA) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Organon & Co. Common Stock — how do they compare? iShares Core MSCI EAFE ETF trades at $95.53 (market cap $188.94B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 52.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares Core MSCI EAFE ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 41 Days and Organon & Co. Common Stock for 0 Days on average.
| IEFA | OGN | |
|---|---|---|
Market Cap | $188.94B | $3.62B |
Volume | 6,200,262 | 2,892,999 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $13.81 |
52-Week Low | $85.06 | $5.70 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA, the iShares Core MSCI EAFE ETF, trades at $96.64, up 0.48% on the day, while technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF provides exposure to developed markets outside North America, managing $196 billion in assets. Recent news highlights its size advantage and higher dividend yield compared to peers, though some competitors have shown stronger recent returns.
The outlook for IEFA is mixed, with bearish technicals offset by its low-cost, diversified international exposure. Opportunities include defensive shifts in investor flows away from concentrated U.S. tech, while risks involve underperformance versus broader global funds and capped upside in strategies like covered calls on the ETF.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
